Aurothiomalate-Based Drugs as Potentially Novel Agents Against Leishmania major: A Mini Review.

Acta Parasitol

Toxoplasmosis Research Center, Communicable Diseases Institute, Iranian National Registry Center for Lophomoniasis and Toxoplasmosis, School of Medicine, Mazandaran University of Medical Sciences, Farah Abad, 48471-91971, Sari, Iran.

Published: June 2022

Purpose: Leishmaniasis is a major public health problem worldwide in many parts of the world. Current anti-leishmanial drugs have only limited clinical efficacy. Aurothiomalate derivatives are useful for treating rheumatoid arthritis, but have emerged as a promising therapeutic candidate for leishmaniasis. This paper gives a review of the literature about the usefulness of aurothiomalate derivatives against leishmaniasis.

Methods: In this study, we reviewed the proposed mechanisms of action of aurothiomalate and related compounds on the metabolism of L. major and collected data by searching relevant articles.

Results: Aurothiomalate-based drugs could be effective against leishmaniasis through two direct and indirect mechanisms: first, cytotoxic effects on parasites via thiomalate's false substrate role in the citric acid cycle against malate; and second, immunosuppressive and anti-inflammatory effects of aurothiomalate derivatives with prostaglandin production inhibitory effects.

Conclusions: The current study documented that aurothiomalate-based drugs could be effective against leishmaniasis through two direct and indirect mechanisms of action. Gold thiomalate as a promising hit should be evaluated against L. major in vitro and in vivo conditions in the future.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11686-022-00536-2DOI Listing

Publication Analysis

Top Keywords

aurothiomalate-based drugs
12
aurothiomalate derivatives
12
mechanisms action
8
drugs effective
8
effective leishmaniasis
8
leishmaniasis direct
8
direct indirect
8
indirect mechanisms
8
drugs novel
4
novel agents
4

Similar Publications

Aurothiomalate-Based Drugs as Potentially Novel Agents Against Leishmania major: A Mini Review.

Acta Parasitol

June 2022

Toxoplasmosis Research Center, Communicable Diseases Institute, Iranian National Registry Center for Lophomoniasis and Toxoplasmosis, School of Medicine, Mazandaran University of Medical Sciences, Farah Abad, 48471-91971, Sari, Iran.

Purpose: Leishmaniasis is a major public health problem worldwide in many parts of the world. Current anti-leishmanial drugs have only limited clinical efficacy. Aurothiomalate derivatives are useful for treating rheumatoid arthritis, but have emerged as a promising therapeutic candidate for leishmaniasis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!